Alnylam initiates kardia-2 phase 2 study of investigational zilebesiran (aln-agt) in patients with inadequately controlled hypertension

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced initiation of kardia-2, a global phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as aln-agt), an investigational subcutaneous rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of hypertension. kardia-2 will evaluate the efficacy and safety of zilebesiran administered biannually as
ALNY Ratings Summary
ALNY Quant Ranking